Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Moderna Inc (MRNA)

Moderna Inc (MRNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 21,216,122
  • Shares Outstanding, K 394,939
  • Annual Sales, $ 1,944 M
  • Annual Income, $ -2,822 M
  • EBIT $ -3,074 M
  • EBITDA $ -2,926 M
  • 60-Month Beta 1.33
  • Price/Sales 11.11
  • Price/Cash Flow N/A
  • Price/Book 2.47

Options Overview Details

View History
  • Implied Volatility 76.32% (-1.38%)
  • Historical Volatility 46.63%
  • IV Percentile 71%
  • IV Rank 45.21%
  • IV High 103.33% on 11/03/25
  • IV Low 54.03% on 08/06/25
  • Expected Move (DTE 5) 3.54 (6.60%)
  • Put/Call Vol Ratio 0.08
  • Today's Volume 133,680
  • Volume Avg (30-Day) 45,589
  • Put/Call OI Ratio 0.98
  • Today's Open Interest 814,552
  • Open Int (30-Day) 822,220
  • Expected Range 50.18 to 57.26

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 24 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-2.27
  • Number of Estimates 10
  • High Estimate $-1.65
  • Low Estimate $-4.36
  • Prior Year $-2.52
  • Growth Rate Est. (year over year) +9.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
47.14 +13.96%
on 03/30/26
56.06 -4.17%
on 04/17/26
-0.21 (-0.39%)
since 03/17/26
3-Month
36.65 +46.56%
on 02/11/26
59.55 -9.79%
on 03/04/26
+11.89 (+28.42%)
since 01/16/26
52-Week
22.28 +141.11%
on 11/21/25
59.55 -9.79%
on 03/04/26
+29.01 (+117.36%)
since 04/17/25

Most Recent Stories

More News
Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026 AACR Annual Meeting

The U.S. FDA has granted Fast Track designation for mRNA-4359 in combination with pembrolizumab for the treatment of checkpoint inhibitor refractory unresectable or metastatic melanoma with PD-L1+ (TPS>1%)...

MRNA : 53.72 (-1.76%)
Moderna to Report First Quarter 2026 Financial Results on Friday, May 1, 2026

CAMBRIDGE, MA / ACCESS Newswire / April 15, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, May 1,2026 to report its first...

MRNA : 53.72 (-1.76%)
3 Unpopular Stocks We Approach with Caution

3 Unpopular Stocks We Approach with Caution

VAL : 88.56 (-6.33%)
MRNA : 53.72 (-1.76%)
PUMP : 13.96 (-5.42%)
3 Mid-Cap Stocks We’re Skeptical Of

3 Mid-Cap Stocks We’re Skeptical Of

IP : 37.13 (+2.60%)
MRNA : 53.72 (-1.76%)
RGA : 211.07 (+1.12%)
Moderna Is Most Shorted S&P 500 Stock Now. Is It a Contrarian Buy?

Moderna is the most shorted S&P 500 stock, with 17.8% short float. But its cancer pipeline, flu approval, and international contracts may surprise bears in 2026.

$SPX : 7,126.06 (+1.20%)
MRK : 119.07 (+3.13%)
MRNA : 53.72 (-1.76%)
Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026

CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present late-breaking oral presentations on revaccination data for both mRNA-1010, its...

MRNA : 53.72 (-1.76%)
2 S&P 500 Stocks with Exciting Potential and 1 We Ignore

2 S&P 500 Stocks with Exciting Potential and 1 We Ignore

TPL : 422.58 (-0.87%)
AMD : 278.39 (+0.05%)
MRNA : 53.72 (-1.76%)
Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know

Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know

HIMS : 28.82 (+6.78%)
BMRN : 54.64 (+1.00%)
REGN : 750.57 (+0.61%)
MRNA : 53.72 (-1.76%)
BIIB : 177.35 (+0.76%)
Cathie Wood Adds 48K Shares to This Under-the-Radar Growth Play

Wood trimmed stakes in Nvidia, Meta, and Tesla; instead, she added this speculative biotech play.

NVDA : 201.68 (+1.68%)
META : 688.55 (+1.73%)
TSLA : 400.62 (+3.01%)
ARKG : 30.79 (+3.18%)
$SPX : 7,126.06 (+1.20%)
AMD : 278.39 (+0.05%)
ARCT : 8.85 (+0.11%)
MRNA : 53.72 (-1.76%)
Azenta, 10x Genomics, PacBio, Oscar Health, and Moderna Shares Plummet, What You Need To Know

Azenta, 10x Genomics, PacBio, Oscar Health, and Moderna Shares Plummet, What You Need To Know

TXG : 26.08 (+3.33%)
PACB : 1.6900 (+3.68%)
OSCR : 15.79 (+1.02%)
AZTA : 25.04 (+2.96%)
MRNA : 53.72 (-1.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Moderna, Inc. is a clinical-stage pharmaceutical company, primarily focused on discovering and developing messenger RNA (mRNA) based therapies. The company's mRNA based COVID-19 vaccine, Spikevax (mRNA-1273), is approved for use in adults in the United States. The vaccine is also authorized for emergency...

See More

Key Turning Points

3rd Resistance Point 58.65
2nd Resistance Point 57.35
1st Resistance Point 55.54
Last Price 53.72
1st Support Level 52.43
2nd Support Level 51.13
3rd Support Level 49.32

See More

52-Week High 59.55
Last Price 53.72
Fibonacci 61.8% 45.31
Fibonacci 50% 40.92
Fibonacci 38.2% 36.52
52-Week Low 22.28

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.